<p><strong>CNS Pharmaceuticals Inc.</strong> (NASDAQ:CNSP) shares are up during Wednesday's premarket session.</p>



<p>The company on Tuesday announced a strategic pivot to acquire clinical-stage assets with identifiable near-term value, sending shares higher and then closing around 9% on Tuesday.</p>



<p>The move follows the recent news of a capital raise, where CNS Pharmaceuticals has entered into securities purchase agreements to sell 650,000 shares at a price of $2.30 each, along with pre-funded warrants for 9,143,479 shares at $2.299 per warrant, expected to close around May 5, 2026.</p>



<p>The company aims to use these funds to support its new corporate strategy announced in March 2026.</p>



<div>


<p>
<strong>
Read Also:

Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View
</strong>
</p>


</div>


<h2>CNS Pharmaceuticals Pivot: Acquisition-Driven Neurology And Oncology Pipeline</h2>



<p>CNS Pharmaceuticals is pivoting from its previous focus on glioblastoma multiforme treatments to a new growth strategy centered on building a high-value pipeline in neurology and oncology.</p>



<p>This shift includes actively discussing out-licensing its legacy glioblastoma programs, allowing the company to focus on acquiring differentiated assets with strong clinical and commercial potential.</p>



<h2>CNSP Technical Outlook: Bullish Momentum And Key Levels</h2>



<p>The stock's current price of $7.63 is significantly above its 20-day simple moving average (SMA) of $2.92, indicating strong bullish momentum.</p>



<p>The relative strength index (RSI) currently sits at 81.59, suggesting that the stock is overbought, which may indicate a potential pullback in the near term.</p>



<p><strong>Key Resistance</strong>: $9.00 — a nearby level where rebounds can stall. <strong>Key Support</strong>: $5.88 — This level aligns with the 200-day SMA, providing a potential floor for the stock.</p>



<h2>How CNSP Ranks On Momentum Versus The Market</h2>



<p>Below is the Benzinga Edge scorecard for CNS Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:</p>



<ul>
<li><strong>Momentum</strong>: Weak (Score: 25.37) — Stock is underperforming the broader market.</li>
</ul>



<p><strong>The Verdict:</strong> CNS Pharmaceuticals' Benzinga Edge signal reveals a weak profile, indicating challenges in gaining traction within the market. The company's focus on a new strategic direction may provide future opportunities, but current momentum suggests caution for investors.</p>



<p><strong>CNSP Price Action:</strong> CNS Pharmaceuticals shares were up 4.90% at $7.50 at the time of publication on Wednesday, according to Benzinga Pro data.</p>



<p>Photo: Gorodenkoff via Shutterstock</p>



<div>


<p><strong>
Read Also:

Top 2 Tech Stocks That May Fall Off A Cliff This Month
</strong></p>


</div>

CNSP

LABU

ARKG

SBIO

<p>CNS Pharmaceuticals Inc. (NASDAQ:CNSP) is shifting to an acquisition-led strategy, focusing on clinical-stage assets in neurology and oncology. The stock rose nearly 9% following the announcement of a capital raise, selling 650,000 shares at $2.30 each. Currently priced at $7.63, the stock shows bullish momentum but is considered overbought, with key resistance at $9.00 and support at $5.88. Despite the strategic pivot, the company's momentum score indicates underperformance compared to the broader market, suggesting caution for investors.</p>

What's Going On With CNS Pharmaceuticals Stock On Wednesday?